Ulonivirine - Merck Sharp & Dohme
Alternative Names: MK-8507Latest Information Update: 25 Apr 2026
At a glance
- Originator Merck Sharp & Dohme
- Class Antiretrovirals; Benzonitrile; Chlorinated hydrocarbons; Ethers; Fluorinated hydrocarbons; Pyridazines; Pyrimidines; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II HIV-1 infections
Most Recent Events
- 15 Apr 2026 Merck Sharp & Dohme plans a phase I (MK-8507-018) pharmacokinetics trial in Healthy volunteers (PO, Tablet) in May 2026 (NCT07530289)
- 09 Apr 2026 Merck Sharp & Dohme completes a phase I trial for HIV-1 infections (In volunteers) in USA (PO, Tablet) (NCT07305831)
- 22 Jan 2026 Merck Sharp & Dohme initiates a phase I trial for HIV-1 infections (In volunteers) in USA (PO, Tablet) (NCT07305831)